cobas® EZH2 Mutation Test

FDA Premarket Approval P200014 S003

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the revised instructions for use for the cobas® ezh2 mutation test.

Devicecobas® EZH2 Mutation Test
Generic NameSomatic Gene Mutation Detection System
ApplicantRoche Molecular System, Inc.
Date Received2021-02-22
Decision Date2021-08-10
PMAP200014
SupplementS003
Product CodeOWD 
Advisory CommitteePathology
Supplement TypeNormal 180 Day Track No User Fee
Supplement ReasonLabeling Change - Pas
Expedited ReviewNo
Combination Product No
Applicant Address Roche Molecular System, Inc. 4300 Hacienda Drive pleasanton, CA 94588

Supplemental Filings

Supplement NumberDateSupplement Type
P200014Original Filing
S004 2022-10-18 30-day Notice
S003 2021-02-22 Normal 180 Day Track No User Fee
S002
S001 2020-07-27 30-day Notice

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.